<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05087342</url>
  </required_header>
  <id_info>
    <org_study_id>5210364</org_study_id>
    <nct_id>NCT05087342</nct_id>
  </id_info>
  <brief_title>Latino Semaglutide Study</brief_title>
  <acronym>LSS</acronym>
  <official_title>A Randomized Latino Semaglutide 2.4mg Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Warren Peters, MD, MPH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Loma Linda University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study to understand better how this anti-obesity medication works to&#xD;
      assist individuals to lose weight and maintain weight loss. This study may lead to the&#xD;
      development of other related medications for assisting people with the disease of obesity.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 14, 2022</start_date>
  <completion_date type="Anticipated">August 14, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 14, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of weight loss.</measure>
    <time_frame>Change between baseline and final study visit, seven months post baseline.</time_frame>
    <description>Assessment will be based on pounds lost between baseline and final study visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Food Addiction Assessment</measure>
    <time_frame>Change between baseline and month four of treatment.</time_frame>
    <description>Yale Food Addiction Scale Survey administered to subjects at baseline and month four of treatment. Assessment results based on multiple survey questions regarding intake of specific food types (sugar, starch, sweet, salty, savory).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Obesity</condition>
  <condition>Obesity; Drug</condition>
  <condition>Overweight or Obesity</condition>
  <condition>Weight Loss</condition>
  <condition>Weight Loss Trajectory</condition>
  <condition>Weight, Body</condition>
  <arm_group>
    <arm_group_label>Intervention Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Will receive active medication semaglutide subcutaneously, once weekly, self-injection.&#xD;
Month 1 - 0.24 mg SC once weekly x 4 weeks.(IE-1) Month 2- 0.5 mg SC once weekly x 4 weeks.(IE-2) Month 3 -1 mg SC once weekly x 4 weeks.(IE-3) Month 4 - 1.7 mg SC once weekly x 4 weeks.(IE-4) Month 5 - 2.4 mg SC once weekly x 4 weeks. (IE-5) Month 6 - 2.4 mg SC continue once weekly x 8 weeks.(IE-6) Month 7 - completion visit (IE-7)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Will receive placebo, subcutaneously, once weekly, self-injection throughout study duration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Semaglutide 2.4mg</intervention_name>
    <description>The intervention drug, semaglutide 2.4mg will be given to the Intervention Group per the schedule outlined in the armed description.</description>
    <arm_group_label>Intervention Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A placebo will be given to the control group per the schedule outlined in the armed description.</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Self-identify as being of Hispanic/Latino ethnicity&#xD;
&#xD;
          -  BMI &gt;30&#xD;
&#xD;
          -  Age 18-75 years old&#xD;
&#xD;
          -  Able to provide informed consent before any trial related activities&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current cancer treatment&#xD;
&#xD;
          -  Diabetes, Type 1 or Type 2&#xD;
&#xD;
          -  Eating disorders&#xD;
&#xD;
          -  Medication use targeting the GPL-1 system&#xD;
&#xD;
          -  In the last 30 days, attempted to lose weight by lifestyle modification alone or with&#xD;
             the use of anti-obesity medications resulting in more than 5 pounds of weight loss.&#xD;
&#xD;
          -  History of bariatric surgery&#xD;
&#xD;
          -  Use of obesogenic medications (including but not limited to steroids, haloperidol,&#xD;
             clozapine, risperidone, olanzapine, amitriptyline, imipramine, paroxetine, and&#xD;
             lithium) which cannot be substituted or stopped.&#xD;
&#xD;
          -  Pregnant or planning to become pregnant in the next 8 months&#xD;
&#xD;
          -  Genetic disorders and/or physical or mental handicaps that would limit participation&#xD;
             in the study and/or the intensive lifestyle intervention.&#xD;
&#xD;
          -  Any contraindication to semaglutide 2.4 mg including personal or family history of&#xD;
             medullary thyroid carcinoma or Multiple Endocrine Neoplasia Syndrome Type 2,&#xD;
             hypersensitivity to semaglutide 2.4 mg or any product components.&#xD;
&#xD;
          -  Any known or suspected allergy to semaglutide 2.4 mg or related products&#xD;
&#xD;
          -  Previous participation in this trial, either initial screening or group randomization&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Warren Peters, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Loma Linda University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Warren Peters, MD</last_name>
    <phone>(909) 558-4594</phone>
    <email>wpeters@llu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lindsay Kerichenko, BS</last_name>
    <phone>(909) 558-4920</phone>
    <email>lkerichenko@llu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Loma Linda University Health</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92350</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Warren Peters, MD</last_name>
      <phone>909-558-4920</phone>
      <email>wpeters@Llu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lindsay Kerichenko, BS</last_name>
      <phone>909-558-4920</phone>
      <email>lkerichenko@llu.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 20, 2021</study_first_submitted>
  <study_first_submitted_qc>October 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 21, 2021</study_first_posted>
  <last_update_submitted>October 8, 2021</last_update_submitted>
  <last_update_submitted_qc>October 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Loma Linda University</investigator_affiliation>
    <investigator_full_name>Warren Peters, MD, MPH</investigator_full_name>
    <investigator_title>Medical Director, Center for Health Promotion, Loma Linda University and Associate Professor, School of Medicine, Loma Linda University</investigator_title>
  </responsible_party>
  <keyword>obesity</keyword>
  <keyword>obesity; drug</keyword>
  <keyword>overweight</keyword>
  <keyword>weight loss</keyword>
  <keyword>weight</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Body Weight</mesh_term>
    <mesh_term>Overweight</mesh_term>
    <mesh_term>Weight Loss</mesh_term>
    <mesh_term>Body-Weight Trajectory</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

